ELEOS™ with NanoCept® Technology Limb Salvage System

K253066 · Onkos Surgical, Inc. · QZZ · Jun 8, 2026 · Orthopedic

Device Facts

• Record ID: K253066
• Device Name: ELEOS™ with NanoCept® Technology Limb Salvage System
• Applicant: Onkos Surgical, Inc.
• Product Code: QZZ · Orthopedic
• Decision Date: Jun 8, 2026
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3900
• Device Class: Class 2
• Attributes: Therapeutic

Indications for Use

The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is indicated for resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia in skeletally mature patients with the following conditions: 1. Non-inflammatory degenerative joint disease such as osteoarthritis, traumatic arthritis, avascular necrosis, ankylosis, protrusion acetabuli, and painful hip dysplasia; 2. Inflammatory degenerative joint disease such as rheumatoid arthritis; 3. Correction of functional deformity; 4. Revision procedures where other treatments or devices have failed; and, 5. Treatment of fractures that are unmanageable using other techniques. The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is also indicated for procedures where resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia is required with the following conditions: 1. Patients suffering from severe arthropathy of the hip and/or knee that does not respond to any conservative therapy or better alternative surgical treatment; 2. Surgical intervention for severe trauma, revision hip or knee arthroplasties, and/or Oncology indications. 3. Metastatic diseases The ELEOS™ with NanoCept® Technology MDPB coating, where applied, is intended to reduce bacterial contamination prior to implantation resulting from deposition in the operating room on the surface of the device components. The clinical impact associated with the MDPB coating, including prevention of infection or reduction of infection risk in patients, has not been evaluated in human clinical trials. The MDPB coating is not intended to treat existing infections and does not act within or on the body.

Device Story

Limb salvage system hardware for bone loss treatment (cancer, trauma, revision); includes non-articulating, non-porous TAV components with MDPB antibacterial coating. Coating reduces bacterial contamination on device surface during OR handling; not for treating existing infections; does not act within/on body. System components implanted by surgeons during orthopedic procedures. Subject device represents line extension of previously cleared ELEOS system; adds TAV components coated with MDPB. Performance testing confirms coating integrity on TAV substrates and ensures MDPB exposure levels remain within limits established by predicate by restricting assembly configurations.

Clinical Evidence

No clinical data. Clinical impact of MDPB coating, including infection prevention or risk reduction, has not been evaluated in human clinical trials. Evidence is limited to bench testing regarding coating integrity and exposure calculations.

Technological Characteristics

Limb salvage system components; materials include TAV (Titanium-Aluminum-Vanadium) and CoCr; surface modification includes MDPB (methacryloyloxydodecyl pyridinium bromide) quaternary ammonium compound coating. System is non-articulating and non-porous. No software or electronic components.

Indications for Use

Indicated for skeletally mature patients requiring resection and replacement of proximal femur, intercalary femur, total femur, distal femur, or proximal tibia due to non-inflammatory/inflammatory degenerative joint disease, functional deformity, failed revision procedures, unmanageable fractures, severe arthropathy, severe trauma, or metastatic disease.

Regulatory Classification

Identification

A limb and joint salvage device with quaternary ammonium compound coating is a metallic implant with or without polymer bearing for bone and joint replacement. Implants are for resection and replacement of an extremity bone (including the entire bone, epiphyseal bone, metaphyseal bone, or diaphyseal bone), or an extremity bone and the surrounding joint(s) in a skeletally mature patient. The device includes a quaternary ammonium compound coating that is covalently bonded to the device, intended to reduce microbial contamination on the surface of the device prior to implantation.

Special Controls

In combination with the general controls of the FD&C Act. the limb and joint salvage device with quaternary ammonium compound coating is subject to the following special controls: - (1) Animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Animal testing must include imaging, histology. and histomorphometry to assess bone formation, healing, and tissue response at relevant timepoints over the course of healing. - (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and include the following: - Evaluation of the static and dynamic performance of the implant: (i) - Evaluation of coated implant initial fixation: (ii) - Evaluation of coating integrity: (iii) - Evaluation of range of motion; (iv) - Evaluation of articulating bearing wear and bearing material; (v) - Evaluation of implant disassembly: (vi) - (vii) Evaluation of fretting and corrosion; - (viii) Evaluation of antimicrobial performance with clinically relevant microbial species; and - (ix) Coating characterization, including a detailed description of the substrate morphology and coating process and an evaluation of coating physicochemical properties such as density, thickness, chemistry, and uniformity. - (3) An analysis must be provided that identifies and evaluates any contribution to the development and spread of antimicrobial resistance. - (4) An analysis or information must be provided to support that the antimicrobial does not act within or on the body. - (5) The patient-contacting components of the device must be demonstrated to be biocompatible. - (6) Performance data must support the sterility and pyrogenicity of the device components intended to be provided sterile. - Performance data must validate the reprocessing instructions for the reusable (7) instrumentation to be used with the device. - Performance data must support the shelf life of the device by demonstrating continued (8) sterility, package integrity, and device functionality over the identified shelf life. - (9) Labeling must include the following: - Identification of device materials; (i) - A shelf life: and (ii) - (iii) Instructions for removal/revision procedures.

Predicate Devices

• ELEOS™ with NanoCept® Technology Limb Salvage System (DEN210058)
• ELEOS Limb Salvage System (K161520)

Reference Devices

• Mariner Pedicle Screw System (DEN220015)

Submission Summary (Full Text)

{0}

**FDA** **U.S. FOOD & DRUG**
ADMINISTRATION

June 8, 2026

Onkos Surgical, Inc.
Arley Perez
Senior Director, Product Development
77 East Halsey Road
Parsippany, New Jersey 07054

Re: K253066

Trade/Device Name: ELEOS Limb Salvage System with NanoCept™ Technology

Regulation Number: 21 CFR 888.3900

Regulation Name: Limb And Joint Salvage Device With Quaternary Ammonium Compound Coating

Regulatory Class: Class II

Product Code: QZZ, KRO, JDI, JWH, LPH, LZO

Dated: May 7, 2026

Received: May 8, 2026

Dear Arley Perez:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K253066 - Arley Perez

Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13484 clause 8.3 (Nonconforming product), and ISO 13485 clause 8.5 (Corrective and preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K253066 - Arley Perez

Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

**LIMIN SUN -S**

Limin Sun, Ph.D.

Assistant Director

DHT6A: Division of Joint

Arthroplasty Devices

OHT6: Office of Orthopedic Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

{3}

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

# Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 07/31/2026

See PRA Statement below.

510(k) Number (if known)

K253066

Device Name

ELEOS™ with NanoCept® Technology Limb Salvage System

Indications for Use (Describe)

The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is indicated for resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia in skeletally mature patients with the following conditions:

1. Non-inflammatory degenerative joint disease such as osteoarthritis, traumatic arthritis, avascular necrosis, ankylosis, protrusion acetabuli, and painful hip dysplasia;
2. Inflammatory degenerative joint disease such as rheumatoid arthritis;
3. Correction of functional deformity;
4. Revision procedures where other treatments or devices have failed; and,
5. Treatment of fractures that are unmanageable using other techniques.

The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is also indicated for procedures where resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia is required with the following conditions:

1. Patients suffering from severe arthropathy of the hip and/or knee that does not respond to any conservative therapy or better alternative surgical treatment;
2. Surgical intervention for severe trauma, revision hip or knee arthroplasties, and/or Oncology indications.
3. Metastatic diseases

The ELEOS™ with NanoCept® Technology MDPB coating, where applied, is intended to reduce bacterial contamination prior to implantation resulting from deposition in the operating room on the surface of the device components. The clinical impact associated with the MDPB coating, including prevention of infection or reduction of infection risk in patients, has not been evaluated in human clinical trials. The MDPB coating is not intended to treat existing infections and does not act within or on the body.

Type of Use (Select one or both, as applicable)

☑ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

FORM FDA 3881 (8/23)

Page 1 of 2

PSC Publishing Services [phone]

EF

{4}

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

[e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (8/23)

Page 2 of 2

{5}

K253066

# ***510(k) Summary***

**Device Trade Name:** ELEOS™ with NanoCept® Technology Limb Salvage System**Common Name:** Limb and joint salvage device with quaternary ammonium compound coating**Manufacturer:** Onkos Surgical, Inc.
77 East Halsey Road
Parsippany, NJ 07054**Contact:** Arley Perez
Senior Director, Product Development
Onkos Surgical, Inc.
77 East Halsey Road
Parsippany, NJ 07463
Phone: [phone]
[e-mail]**Prepared by:** MCRA, LLC
803 7$^{th}$ Street NW
Washington, DC 20001
Office: 202.552.5800**Date Prepared:** 08 June 2026**Classifications:** **21 CFR 888.3900**
**Limb and joint salvage device with quaternary ammonium compound coating***Class:** II**Product Codes:** QZZ, KRO, JDI, JWH, LPH, LZO**Primary Predicate:** ELEOS™ with NanoCept® Technology Limb Salvage System
(*DEN210058*)**Additional Predicates:** ELEOS Limb Salvage System (K161520)**Reference Device:** Mariner Pedicle Screw System (DEN220015)

Page 1 of 3

{6}

K253066

# **Indications For Use:**

The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is indicated for resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia in skeletally mature patients with the following conditions:

1. Non-inflammatory degenerative joint disease such as osteoarthritis, traumatic arthritis, avascular necrosis, ankylosis, protrusion acetabuli, and painful hip dysplasia;
2. Inflammatory degenerative joint disease such as rheumatoid arthritis;
3. Correction of functional deformity;
4. Revision procedures where other treatments or devices have failed; and,
5. Treatment of fractures that are unmanageable using other techniques.

The ELEOS™ and ELEOS™ with NanoCept® Technology Limb Salvage System is also indicated for procedures where resection and replacement of the proximal femur, intercalary portion of the femur, total femur, distal femur, and proximal tibia is required with the following conditions:

1. Patients suffering from severe arthropathy of the hip and/or knee that does not respond to any conservative therapy or better alternative surgical treatment;
2. Surgical intervention for severe trauma, revision hip or knee arthroplasties, and/or Oncology indications.
3. Metastatic diseases

The ELEOS™ with NanoCept® Technology MDPB coating, where applied, is intended to reduce bacterial contamination prior to implantation resulting from deposition in the operating room on the surface of the device components. The clinical impact associated with the MDPB coating, including prevention of infection or reduction of infection risk in patients, has not been evaluated in human clinical trials. The MDPB coating is not intended to treat existing infections and does not act within or on the body.

# **Device Description:**

The ELEOS™ with NanoCept® Technology System consists of hardware for patients who require limb salvage to treat significant bone loss due to cancer, trauma, or previous surgical procedures. Certain CoCr components of the ELEOS™ with NanoCept® Technology System contain an added antibacterial coating, MDPB, that was granted marketing authorization through DEN210058. The subject 510(k) introduces a line extension to the ELEOS™ Limb Salvage System with NanoCept® Technology that includes additional non-articulating, non-porous TAV ELEOS™ with NanoCept® Technology components coated with MDPB. All TAV coated subject devices have previously been cleared as uncoated TAV components of the ELEOS™ System under K161520.

# **Predicate Device:**

Onkos Surgical submits the following information in this Premarket Notification to demonstrate that, for the purposes of FDA's regulation of medical devices, ELEOS™ with NanoCept® Technology

Page 2 of 3

{7}

K253066

Limb Salvage System is substantially equivalent in indications, design principles, and performance to the following predicate device:

Primary Predicate: ELEOS™ with NanoCept® Technology Limb Salvage System (DEN210058)

Secondary Predicates: ELEOS Limb Salvage System (K161520)

### Performance Testing Summary:

The following performance testing was completed to support substantial equivalence:

- Evaluation of coating integrity supported that different substrate material (i.e., TAV vs. CoCr) does not affect the integrity of the MDPB coating.
- Total MDPB-coated surface area was calculated for each assembly configuration to determine if the introduction of the subject TAV MDPB-coated components introduce a new worst-case for MDPB exposure. For the Total Femur and Proximal Tibia configurations, labeling was updated to align with outcomes of the calculation and ensure equivalent MDPB exposure to the predicate, specifically limiting these assemblies to no more than two MDPB-coated components.

### Substantial Equivalence:

The subject ELEOS™ with NanoCept® Technology Limb Salvage System is substantially equivalent to the previously cleared version in DEN210058 with respect to intended use, materials, design, and function.

### Conclusion:

The subject device is substantially equivalent to the predicate device with respect to intended use, materials, design, and function.

Page 3 of 3